CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Therapeutics, a privately held biotechnology company applying deep computational expertise throughout drug discovery and development, today announced that it has raised $65 million in new capital to accelerate the company’s pipeline progress and fuel its expansion into new high-value targets aimed at overlapping biological mechanisms in immunology, oncology and metabolic disease. Each of the company’s current investors participated in the financing, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures, and Schrödinger. Bruce Booth, Partner of Atlas Venture, Board Chair and co-founder of Nimbus noted, “this round of investment reflects the existing syndicate’s strong and enthusiastic support for Nimbus’ proven management team and exciting new programs.”
“The continued support from our world-class investor base is testament to our team’s repeated success in designing and developing promising candidates through our unique combination of massive computational-chemistry horsepower with founding partner, Schrödinger, coupled with additional cutting-edge technologies in structural biology, cryo-EM, and machine learning-augmented ADMET prediction to rapidly advance our pipeline to the clinic,” said Don Nicholson, Ph.D., Chief Executive Officer. “We have made substantial progress across our entire portfolio, including inhibitors of Tyk2 (tyrosine kinase 2) and antagonists of STING (stimulator of interferon genes), both under our immunology alliance with Celgene. Additionally, our wholly owned STING agonist program has generated novel, highly potent, bona fide small molecules with compelling preclinical data.”
“This most recent infusion of capital from our investors, together with proceeds from business development activity, enables Nimbus to remain a privately held LLC organization, which has allowed us to transact multiple deals with world leading partners such as Gilead, Celgene, and Genentech,” said Jeb Keiper, Chief Financial Officer and Chief Business Officer. “Nimbus’ success has built a nine-figure balance sheet of resources for the rapid advancement and expansion of our pipeline and technology, which will allow us to develop several other undisclosed target programs forward to the clinic in the next few years.”
About Tyk2 (tyrosine kinase 2)
Tyk2 is an important
signal-transduction kinase for key pro-inflammatory cytokine receptors,
including IL-23, IL-12 and interferons α and β. As a result, Tyk2 is a
key target for the treatment of several challenging auto-immune
disorders, including SLE (lupus), Crohn’s disease, psoriasis, multiple
sclerosis, rheumatoid arthritis and others. In addition, some cancers,
like T-ALL, appear to be driven by Tyk2 hyper-activation and are
responsive to Tyk2 inhibition. Nimbus’ Tyk2 program is partnered under
the immunology alliance with Celgene.
About STING (STimulator of INterferon Genes)
STING agonism
(turning STING “on”) plays a key role in anti-tumor immunity by
activation of the innate immune system and induction of the Type-I
interferon response, leading to recruitment and activation of cytotoxic
T lymphocytes that attack tumor cells. STING agonism provokes anti-tumor
responses alone, and in combination with checkpoint inhibitors and cell
therapy. Further, STING agonists have been shown to provide benefit in
areas of virology, such as efforts to achieve HIV cure. STING
antagonists (turning STING “off”) may have therapeutic potential in
Type-I interferonopathies, such as SLE (lupus), where STING drives an
exaggerated interferon response. Nimbus’ STING antagonist program is
partnered under the immunology alliance with Celgene, while the STING
agonist program remains wholly owned by Nimbus.
About Nimbus Therapeutics
Nimbus Therapeutics is a
biotechnology company headquartered in Cambridge, Massachusetts (USA).
Nimbus is pioneering the application of highly-advanced computational
technologies to the design and development of novel treatments for
substantial and underserved human diseases. The company’s focus on
metabolic diseases, cancer and immune-inflammatory disorders reflects
the mechanistic relationship between these disorders, and Nimbus’
ability to rapidly tackle well validated targets as well as those that
have proven intractable to others. The company’s LLC/subsidiary
architecture enables diverse and synergistic partnerships to deliver
breakthrough medicines. To learn more, please visit www.nimbustx.com.
